Illumina Sees Strong Clinical Demand, but Research Recovery Remains in Question
Illumina reports strong clinical demand, particularly in the U.S., with increased sequencing instrument placements. The company expects mid-single-digit growth through 2026 and aims for 25% operating margins in Q4, supporting its margin-expansion goal, according to the company.




